ISRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Intuitive Surgical Inc (ISRG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and heavy congressional buying outweigh the current bearish technical indicators. The long-term growth potential of its da Vinci systems and leadership in robotic-assisted surgery make it a compelling investment opportunity.
The technical indicators are currently bearish. The MACD is negatively expanding (-0.57), RSI is neutral (27.348), and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near a key support level (S1: 471.103), with resistance at R1: 505.743. This suggests limited short-term upside but does not negate long-term potential.
Strong financial performance in Q4 2025 with revenue up 18.76% YoY, net income up 15.91% YoY, and EPS up 17.55% YoY.
Positive analyst sentiment with multiple upgrades and price target increases, including Barclays raising its target to $712 and Bernstein to $
Strong demand for da Vinci systems, with a 12% YoY increase in the installed base and 19% revenue growth in the robotic-assisted surgery market.
Heavy congressional buying, with $1.5M-$5.0M in purchases over the past 90 days, indicating confidence from influential figures.
Bearish technical indicators, including a negatively expanding MACD and bearish moving averages.
Recent stock decline of 13% over the past year due to high tariffs and increased competition.
Gross margin dropped by 2.35% YoY in Q4 2025, indicating potential cost pressures.
In Q4 2025, Intuitive Surgical reported strong financials with revenue increasing by 18.76% YoY to $2.87 billion, net income rising by 15.91% YoY to $794.8 million, and EPS growing by 17.55% YoY to $2.21. However, gross margin dropped to 66.44%, down 2.35% YoY, indicating some margin pressure.
Analysts are overwhelmingly positive on ISRG, with multiple upgrades and price target increases. Notable upgrades include Freedom Capital upgrading to Buy with a $610 target, TD Cowen initiating coverage with a $660 target, and Barclays raising its target to $712. Analysts cite strong growth potential, the rollout of the da Vinci 5 system, and leadership in robotic-assisted surgery as key drivers.
